arrow
C

Claudio Nicotra

unicancer
H指数:19
被引数:1,516

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Deciphering resistance mechanisms in cancer: final report of MATCH-R study with a focus on molecular drivers and PDX development

破译癌症的耐药机制: MATCH-R研究的最终报告,重点是分子驱动和PDX的发展

2024-10-040
OAAI
Organoids for Functional Precision Medicine in Advanced Pancreatic Cancer

用于晚期胰腺癌功能精准医学的类器官

2024-10-012
OA
Development of Novel Models of Aggressive Variants of Castration-resistant Prostate Cancer

去势抵抗性前列腺癌侵袭性变异体新模型的建立

2024-06-011
PRE
Codon-specific KRAS mutations predict survival in advanced pancreatic cancer
2024-01-160
PRE
Molecular profiling of biliary tract cancers reveals distinct genomic landscapes between circulating and tissue tumor DNA

胆道癌的分子谱分析揭示了循环和组织肿瘤DNA之间不同的基因组景观

2024-01-084
OA
Circulating tumor DNA landscape and prognostic impact of acquired resistance to targeted therapies in cancer patients: a national center for precision medicine (PRISM) study
2023-11-044
OAAI
MatchR a preclinical platform of models resistant to innovative therapies

MatchR是对创新疗法有抵抗力的模型的临床前平台

2023-04-040
PRE
Molecular landscape of clonal hematopoiesis in patients with lung cancer: First results of the CHIC study
2023-04-040
PRE
Clinical utility of liquid biopsy for molecular characterization and resistance detection in patients with advanced NSCLC and ALK, ROS1 or RET fusions
2023-04-040
PRE
Clinical utility of circulating tumor DNA sequencing with a large panel: a National Center for Precision Medicine (PRISM) study
2023-04-0132
OAAI
Liquid versus tissue biopsy for detecting actionable alterations according to the ESMO Scale for Clinical Actionability of molecular Targets in patients with advanced cancer: a study from the French National Center for Precision Medicine (PRISM)
2022-12-0125
OA
Epigenetic gene alterations in metastatic solid tumours: results from the prospective precision medicine MOSCATO and MATCH-R trials
2022-09-011
PRE
Clinical Utility and Outcomes Impact of Crystal Digital PCR of Sensitizing and Resistance EGFR Mutations in Patients With Advanced Non-Small Cell Lung Cancer
2022-09-010
OAAI
Next-Generation Sequencing on Circulating Tumor DNA in Advanced Solid Cancer: Swiss Army Knife for the Molecular Tumor Board? A Review of the Literature Focused on FDA Approved Test
CELLS
IF5.2
2022-06-1112
OAAI